Novartis AG ADR (NVS)vsRegenxbio Inc (RGNX)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
RGNX
Regenxbio Inc
$6.88
+2.84%
HEALTHCARE · Cap: $331.38M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 64323% more annual revenue ($56.58B vs $87.82M). NVS leads profitability with a 23.9% profit margin vs 0.0%. RGNX appears more attractively valued with a PEG of 0.26. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
RGNX
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for RGNX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Growing faster than its price suggests
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Trading at 16.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : RGNX
The strongest argument for RGNX centers on PEG Ratio. PEG of 0.26 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : RGNX
The primary concerns for RGNX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.37 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while RGNX is a value play — different risk/reward profiles.
RGNX carries more volatility with a beta of 1.03 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 35/100), backed by strong 23.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Regenxbio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?